Retrophin to Present at the Jefferies 2017 Global Healthcare Conference

SAN DIEGO, May 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Tuesday, June 6, 2017 at 3:30 p.m. ET.

A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay will be accessible for up to 30 days.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Thiola®, Cholbam®, and Chenodal®.

Retrophin.com

Contact:
Chris Cline, CFA
Vice President, Investor Relations & Corporate Communications
646-564-3680
[email protected]

You May Also Be Interested In

• Buddy Brings Native Ecommerce to Flowhub Dispensaries, Live in 24 Hours
• HAKLO Announces General Availability of Family Culture App
• TTW Announces the Top 50 Travel Solution Cards in the World for 2026